| Publications | PubMed=23891627; DOI=10.1016/j.ajog.2013.07.020
Diana P. English, Stefania Bellone, Emiliano Cocco, Ileana Bortolomai, Sergio Pecorelli, Salvatore Lopez, Dan-Arin Silasi, Peter E. Schwartz, Thomas J. Rutherford, Alessandro D. Santin;
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Am. J. Obstet. Gynecol. 209:465.e1-465.e9(2013) PubMed=25268372; DOI=10.1038/bjc.2014.519; PMCID=PMC4453741
Carlton L. Schwab, Stefania Bellone, Diana P. English, Dana Marie Roque, S. Lopez, Emiliano Cocco, Roberta Nicoletti, Ileana Bortolomai, Elena Bonazzoli, Elena Ratner, Dan-Arin Silasi ...Show all 15 authors... , Masoud Azodi, Peter E. Schwartz, Thomas J. Rutherford, Alessandro D. Santin; Show fewer authors
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
Br. J. Cancer 111:1750-1756(2014) PubMed=26325104; DOI=10.1038/bjc.2015.306; PMCID=PMC4651122
Jonathan D. Black, Salvatore Lopez, Emiliano Cocco, Stefania Bellone, Gary Altwerger, Carlton L. Schwab, Diana P. English, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Elena Ratner ...Show all 15 authors... , Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin; Show fewer authors
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br. J. Cancer 113:1020-1026(2015) PubMed=26625219; DOI=10.1038/bjc.2015.388; PMCID=PMC4705897
Jonathan D. Black, Salvatore Lopez, Emiliano Cocco, Stefania Bellone, Gary Altwerger, Carlton L. Schwab, Diana P. English, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Elena Ratner ...Show all 15 authors... , Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin; Show fewer authors
Erratum to: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br. J. Cancer 113:1641-1641(2015) |
|---|
